In addition to these two main genetic markers, a number of segmental aberrations involving different chromosomes have also been described that, in addition to MYCN amplification, have a strong effect on the development of neuroblastoma, making it more aggressive and resistant to treatment (Lerone et al., 2021). The gene discussed is MYCN; the disease is neuroblastoma.